You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BTK Intolerant

Showing 1 - 25 of 665
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma Trial in Houston (Trabectedin, Venetoclax)

Withdrawn
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 11, 2020

r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

Not yet recruiting
  • B-cell Lymphoma
  • Beijing, Beijing, China
    Deparment of Hematology, Peking University People's Hospital
Aug 9, 2022

Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • +2 more
  • (no location specified)
Jul 18, 2023

Acute Myeloid Leukemia, MDS Trial in United States (CG-806)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Duarte, California
  • +9 more
Mar 4, 2022

Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in United States (Ibrutinib,

Active, not recruiting
Has Results
  • Metastatic Melanoma
  • +2 more
  • Los Angeles, California
  • +12 more
Jul 27, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome Trial in Italy, United Kingdom, United States

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
  • +11 more
Nov 23, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Zhengzhou, Nanjing (TQB3909 tablet)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • TQB3909 tablet
  • Zhengzhou, Henan, China
  • +1 more
Jul 17, 2023

CLL/SLL Trial (lisaftoclax +BTK inhibitor, BTK inhibitor)

Not yet recruiting
  • CLL/SLL
  • lisaftoclax +BTK inhibitor
  • BTK inhibitor
  • (no location specified)
Oct 26, 2023

Mature B Cell Tumors Trial in Tianjin (SHR1459)

Active, not recruiting
  • Mature B Cell Neoplasms
  • Tianjin, Tianjin, China
    Blood disease hospital of Chinese Academy of Medical Sciences
Nov 10, 2022

Chronic Lymphocytic Leukemia Trial in Germany (Obinutuzumab, Venetoclax, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Bad Saarow, Germany
  • +29 more
May 4, 2022

The Cre8™ BTK Post Market Clinical Follow-up Study

Not yet recruiting
  • Peripheral Arterial Disease
  • Cre8™ BTK
  • Abano Terme, Padova, Italy
  • +1 more
Nov 8, 2022

Atrial Fibrillation Trial in Caen (Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®))

Not yet recruiting
  • Atrial Fibrillation
  • Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
  • Caen, Normandie, France
    Caen University Hospital, Department of Pharmacology
Sep 6, 2023

Warm Autoimmune Hemolytic Anemia Trial in Beijing (Zanubrutinib)

Not yet recruiting
  • Warm Autoimmune Hemolytic Anemia
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jun 20, 2023

Critical Limb Ischemia (CLI) Trial in Australia, Taiwan, United States (Esprit BTK Device)

Recruiting
  • Critical Limb Ischemia (CLI)
  • Esprit BTK Device
  • South Dartmouth, Massachusetts
  • +4 more
Apr 26, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

Recurrent Refractory Mantle Cell Lymphoma

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Peking University Third Hospital
    Aug 1, 2022

    Hypercholesterolemia Trial in Japan (K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily))

    Recruiting
    • Hypercholesterolemia
    • K-877 0.2 mg/day (once daily)
    • +2 more
    • Aichi, Japan
    • +14 more
    Jun 20, 2023

    Mantle Cell Lymphoma (MCL) Trial in China (LP-168)

    Not yet recruiting
    • Mantle Cell Lymphoma (MCL)
    • Hefei, Anhui, China
    • +29 more
    Feb 7, 2023

    Sjögren Syndrome Trial in Worldwide (LOU064, Placebo)

    Terminated
    Has Results
    • Sjögren Syndrome
    • Boston, Massachusetts
    • +25 more
    Jan 27, 2023

    Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM) Trial in Rochester (Shingrix vaccine)

    Completed
    • Chronic Lymphocytic Leukemia (CLL)
    • Waldenstrom Macroglobulinemia (WM)
    • Shingrix vaccine
    • Rochester, New York
      University of Rochester
    Jan 9, 2023

    Newly Diagnosed Mantle Cell Lymphoma Trial in Zhengzhou (Rituximab)

    Recruiting
    • Newly Diagnosed Mantle Cell Lymphoma
    • Zhengzhou, Henan, China
      Department of Oncology, The First Affiliated Hospital of Zhengzh
    Aug 17, 2022

    B-Cell Malignancies Trial (TT-01488 Tablets)

    Not yet recruiting
    • B-Cell Malignancies
    • TT-01488 Tablets
    • (no location specified)
    Jan 4, 2023

    Neuromyelitis Optica Spectrum Disorder Trial in Beijing (Orelabrutinib)

    Not yet recruiting
    • Neuromyelitis Optica Spectrum Disorder
    • Beijing, Beijing, China
      Peking Union Medical College Hospital, Chinese Academy of Medica
    Mar 16, 2022

    CNS Lymphoma Trial in Beijing (Zanubrutinib)

    Recruiting
    • CNS Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Aug 1, 2022